Skip to main content
    L

    LENZ Therapeutics Inc (LENZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.82
    -0.31 (-7.51%)

    Market Cap: $129.77M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    LENZ Therapeutics Inc (LENZ) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    LENZ Therapeutics reported revenue of $19.09M for the fiscal year ended Dec 31, 2025. That year, net income was -$82.13M with a net margin of -430.3%, operating cash flow was -$69.17M and free cash flow was -$70.00M. The quarter ended Sep 30, 2026 had revenue of $3.38M and net income of -$30.97M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$19.09MN/A97.8%-477.5%-430.3%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$19.09M$0$0$0$0$0N/A
    Cost of revenue$418.00K$0$0$0$0$0N/A
    Gross profit$18.67M$0$0$0$0$0N/A
    Research and development$18.67M$29.80M$59.50M$72.79M$37.93M$9.12M$0
    Operating income-$91.14M-$58.61M-$72.43M-$105.64M-$60.44M-$13.50M-$29.00K
    Net income-$82.13M-$49.77M-$69.97M-$101.05M-$70.76M-$68.37M-$109.00K
    EBITDAN/AN/AN/A-$100.30MN/AN/A$142.86K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$3.38M$5.49M$1.90M$1.59M$12.50M$5.00M$0$66.00K$0$0$0$0
    Gross profit$2.93M$5.21M$825.00K$1.17M$12.50M$5.00M$0$33.00K$0$0$0-$142.00K
    Operating income-$32.92M-$34.17M-$44.13M-$38.46M-$18.89M-$16.86M-$16.93M-$15.22M-$12.95M-$14.35M-$16.09M-$24.99M
    Net income-$30.97M-$31.92M-$41.49M-$35.90M-$16.70M-$14.91M-$14.62M-$12.65M-$10.21M-$10.25M-$16.65M-$23.69M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $465.00K by $24.71M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$305.88M$215.30M$70.38M$321.90M$401.99M$22.56M$6.00K
    Current assets$301.41M$211.92M$67.24M$275.37M$381.74M$21.10M$6.00K
    Cash and equivalents$25.18M$20.16M$35.14M$47.73M$376.98M$19.78M$6.00K
    Total liabilities$21.54M$11.22M$19.70M$25.61M$17.94M$32.36M$2.22M
    Short-term debt$465.00K$567.00K$137.00K$103.00KN/AN/A$2.21M
    Shareholder equity$284.34M$204.08M-$92.71M$296.29M$384.05M-$65.41M-$2.22M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$209.75M$236.60M$272.54M$305.88M$210.70M$217.33M$201.25M$215.30M$224.01M$202.64M$217.32M$70.38M
    Total liabilities$17.75M$17.33M$26.04M$21.54M$16.78M$10.97M$9.24M$11.22M$8.73M$9.72M$19.16M$163.09M
    Cash and equivalents$30.55M$24.21M$24.77M$25.18M$25.40M$37.61M$23.04M$20.16M$41.05M$84.03M$200.36M$35.14M
    Shareholder equity$192.00M$219.26M$246.49M$284.34M$193.93M$206.37M$192.01M$204.08M$215.28M$192.92M$198.17M-$92.71M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$69.17M-$59.39M-$60.38M-$87.98M-$52.85M-$8.72M-$19.00K
    Capital expenditures$827.00K$468.00K$30.00K$6.59M$5.74M$1.54M$0
    Free cash flow-$70.00M-$59.86M-$60.41M-$94.57M-$58.59M-$10.27M-$19.00K
    Share repurchasesN/AN/A$2.48M$79.00KN/AN/AN/A
    Investing cash flow-$75.67M-$154.48M-$29.62M-$241.86M-$5.74M-$1.54MN/A
    Financing cash flow$149.75M$199.00M$80.70M$597.00K$417.47M$30.08MN/A
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$22.31M-$38.71M-$33.58M-$33.02M-$8.59M-$11.51M-$16.05M-$9.08M-$10.58M-$15.79M-$23.94M-$20.97M
    Capital expendituresN/A$16.00K$18.00K$38.00K$439.00K$240.00K$110.00K$149.00K$186.00K$133.00K$0$50.00K
    Free cash flowN/A-$38.73M-$33.60M-$33.06M-$9.03M-$11.75M-$16.16M-$9.23M-$10.77M-$15.93M-$23.94M-$21.02M
    Last 12 quarters

    Frequently Asked Questions About LENZ

    What is LENZ Therapeutics' annual revenue?

    LENZ Therapeutics reported revenue of $19.09M for the fiscal year ended Dec 31, 2025.

    Is LENZ Therapeutics profitable?

    No. LENZ Therapeutics reported net income of -$82.13M for the fiscal year ended Dec 31, 2025, with a net margin of -430.3%.

    How much free cash flow does LENZ generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$69.17M minus capital expenditures of $827.00K produced free cash flow of -$70.00M.

    How much debt does LENZ Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $465.00K and cash and equivalents of $25.18M.

    What is LENZ's profit margin?

    For the fiscal year ended Dec 31, 2025, LENZ Therapeutics reported gross margin of 97.8%, operating margin of -477.5% and net margin of -430.3%.